Recursion Pharmaceuticals, Inc. RXRX Free cash flow yield
Free cash flow yield at other companies
Other financials
Where this comes from
Calculated from Recursion Pharmaceuticals, Inc.’s reported figures.
Based on trailing twelve months.
The official record: Recursion Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Recursion Pharmaceuticals, Inc.'s free cash flow yield.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Recursion Pharmaceuticals, Inc.'s free cash flow yield?
- Recursion Pharmaceuticals, Inc. (RXRX) reported free cash flow yield of -20.1% in Q1 2026.
- How has Recursion Pharmaceuticals, Inc.'s free cash flow yield changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s free cash flow yield decreased by 7.4% year-over-year, from -18.7% to -20.1%.
- What is the long-term trend for Recursion Pharmaceuticals, Inc.'s free cash flow yield?
- Over 4 years (2021 to 2025), Recursion Pharmaceuticals, Inc.'s free cash flow yield has grown at a 27.2% compound annual growth rate (CAGR), from -6.8% to -17.8%.
- What does free cash flow yield mean?
- Trailing-twelve-month free cash flow divided by market capitalization at the quarter end. The cash return the business generates relative to its market price.